Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial (Q38316900)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial |
scientific article |
Statements
1 reference
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial (English)
1 reference
Derek C Angus
1 reference
Jean-Louis Vincent
1 reference
Steven M Opal
1 reference
Pierre-Francois Laterre
1 reference
Bruno Francois
1 reference
Steven P LaRosa
1 reference
Xavier Wittebole
1 reference
Thierry Dugernier
1 reference
Dominique Perrotin
1 reference
Mark Tidswell
1 reference
Luis Jauregui
1 reference
Kenneth Krell
1 reference
Jan Pachl
1 reference
Takeshi Takahashi
1 reference
Claus Peckelsen
1 reference
Edward Cordasco
1 reference
Chia-Sheng Chang
1 reference
Sandra Oeyen
1 reference
Naoki Aikawa
1 reference
Tatsuya Maruyama
1 reference
Roland Schein
1 reference
Andre C Kalil
1 reference
Marc Van Nuffelen
1 reference
Melvyn Lynn
1 reference
Daniel P Rossignol
1 reference
Jogadish Gogate
1 reference
Mary B Roberts
1 reference
Janice L Wheeler
1 reference
ACCESS Study Group
1 reference
1 March 2013
1 reference
1 reference
Identifiers
1 reference